Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies
Background Reduced CYP2D6 metabolism and low Z-endoxifen (ENDX) concentrations may increase the risk of breast cancer recurrence in tamoxifen (TAM)-treated women. Little is known regarding the differences between TAM and ENDX murine pharmacokinetics or the effect of administration route on plasma co...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2014-12, Vol.74 (6), p.1271-1278 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1278 |
|---|---|
| container_issue | 6 |
| container_start_page | 1271 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 74 |
| creator | Reid, Joel M. Goetz, Matthew P. Buhrow, Sarah A. Walden, Chad Safgren, Stephanie L. Kuffel, Mary J. Reinicke, Kathryn E. Suman, Vera Haluska, Paul Hou, Xiaonan Ames, Matthew M. |
| description | Background
Reduced CYP2D6 metabolism and low Z-endoxifen (ENDX) concentrations may increase the risk of breast cancer recurrence in tamoxifen (TAM)-treated women. Little is known regarding the differences between TAM and ENDX murine pharmacokinetics or the effect of administration route on plasma concentrations of each drug.
Methods
The pharmacokinetics of TAM and ENDX were characterized in female mice.
Results
For subcutaneous [s.c.] and oral TAM (4, 10 and 20 mg/kg), TAM AUC increased in a linear manner, but concentrations of the active metabolites [ENDX and 4-hydroxytamoxifen (4HT)] remained low. For oral TAM (20 mg), 4HT concentrations were tenfold greater (>25 ng/ml) than achievable in TAM-treated humans. Both oral (10–200 mg/kg) and s.c. (2.5–25 mg/kg) ENDX·HCl resulted in a greater than dose-proportional increase in AUC, with eightfold greater ENDX concentrations than an equivalent TAM dose. ENDX accumulated in plasma after 5-day dosing of 25 or 100 mg/kg ENDX·HCl and exceeded target concentrations of 0.1 and 1.0 μM, respectively, by twofold to fourfold.
Conclusions
In murine models, oral ENDX yields substantially higher ENDX concentrations, compared to TAM. The low 4HT and ENDX concentrations observed in mice receiving s.c. TAM mirror the TAM pharmacokinetics in humans with impaired CYP2D6 metabolism. These data support the ongoing development of ENDX as a novel agent for the endocrine treatment of ER-positive breast cancer. |
| doi_str_mv | 10.1007/s00280-014-2605-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4343319</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3499993201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-b38f34b355da4bc74bbc61dd64fa44e7c9d8f497ad2ccc2fc55b4534224992a93</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS1ERZfCB-CCLCGOAf8ZxwkHJFRBi1SpPZSzNXHs1iWxt3Z2Rb89Xu1SyoHTaGZ-8-ZJj5A3nH3gjOmPhTHRsYZxaETLVKOfkRUHKRrWgXxOVkwCNEozOCYvS7ljjAGX8gU5Fkryrpftitxf3WKe0aafIbol2EKTpy6O6VfwLlKMI11wPnQhUu9mnBydg3WfaJjXU7C4hBQL9SlTm-Y15jrYuh28DdtE0dY2LA-0LJsxuPKKHHmcint9qCfkx7ev16fnzcXl2ffTLxeNVYwtzSA7L2GQSo0Ig9UwDLbl49iCRwCnbT92HnqNo7DWCm-VGkBJEAL6XmAvT8jnve56M8xutC4uGSezzmHG_GASBvPvJoZbc5O2BiRIyXcC7w4COd1vXFnMXdrkWD0b3grVcSWgqxTfUzanUrLzjx84M7uUzD4lU1Myu5SMrjdvn1p7vPgTSwXeHwAsFiefMdpQ_nIVAq1l5cSeK3UVb1x-YvG_338DDOOtWw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1625815248</pqid></control><display><type>article</type><title>Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Reid, Joel M. ; Goetz, Matthew P. ; Buhrow, Sarah A. ; Walden, Chad ; Safgren, Stephanie L. ; Kuffel, Mary J. ; Reinicke, Kathryn E. ; Suman, Vera ; Haluska, Paul ; Hou, Xiaonan ; Ames, Matthew M.</creator><creatorcontrib>Reid, Joel M. ; Goetz, Matthew P. ; Buhrow, Sarah A. ; Walden, Chad ; Safgren, Stephanie L. ; Kuffel, Mary J. ; Reinicke, Kathryn E. ; Suman, Vera ; Haluska, Paul ; Hou, Xiaonan ; Ames, Matthew M.</creatorcontrib><description>Background
Reduced CYP2D6 metabolism and low Z-endoxifen (ENDX) concentrations may increase the risk of breast cancer recurrence in tamoxifen (TAM)-treated women. Little is known regarding the differences between TAM and ENDX murine pharmacokinetics or the effect of administration route on plasma concentrations of each drug.
Methods
The pharmacokinetics of TAM and ENDX were characterized in female mice.
Results
For subcutaneous [s.c.] and oral TAM (4, 10 and 20 mg/kg), TAM AUC increased in a linear manner, but concentrations of the active metabolites [ENDX and 4-hydroxytamoxifen (4HT)] remained low. For oral TAM (20 mg), 4HT concentrations were tenfold greater (>25 ng/ml) than achievable in TAM-treated humans. Both oral (10–200 mg/kg) and s.c. (2.5–25 mg/kg) ENDX·HCl resulted in a greater than dose-proportional increase in AUC, with eightfold greater ENDX concentrations than an equivalent TAM dose. ENDX accumulated in plasma after 5-day dosing of 25 or 100 mg/kg ENDX·HCl and exceeded target concentrations of 0.1 and 1.0 μM, respectively, by twofold to fourfold.
Conclusions
In murine models, oral ENDX yields substantially higher ENDX concentrations, compared to TAM. The low 4HT and ENDX concentrations observed in mice receiving s.c. TAM mirror the TAM pharmacokinetics in humans with impaired CYP2D6 metabolism. These data support the ongoing development of ENDX as a novel agent for the endocrine treatment of ER-positive breast cancer.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-014-2605-7</identifier><identifier>PMID: 25318936</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Administration, Oral ; Animals ; Antineoplastic agents ; Antineoplastic Agents, Hormonal - administration & dosage ; Antineoplastic Agents, Hormonal - pharmacokinetics ; Area Under Curve ; Biological and medical sciences ; Cancer Research ; Cytochrome P-450 CYP2D6 - metabolism ; Dose-Response Relationship, Drug ; Female ; Injections, Subcutaneous ; Medical sciences ; Medicine ; Medicine & Public Health ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Oncology ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Tamoxifen - administration & dosage ; Tamoxifen - analogs & derivatives ; Tamoxifen - pharmacokinetics</subject><ispartof>Cancer chemotherapy and pharmacology, 2014-12, Vol.74 (6), p.1271-1278</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 2014 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-b38f34b355da4bc74bbc61dd64fa44e7c9d8f497ad2ccc2fc55b4534224992a93</citedby><cites>FETCH-LOGICAL-c500t-b38f34b355da4bc74bbc61dd64fa44e7c9d8f497ad2ccc2fc55b4534224992a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-014-2605-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-014-2605-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28934773$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25318936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reid, Joel M.</creatorcontrib><creatorcontrib>Goetz, Matthew P.</creatorcontrib><creatorcontrib>Buhrow, Sarah A.</creatorcontrib><creatorcontrib>Walden, Chad</creatorcontrib><creatorcontrib>Safgren, Stephanie L.</creatorcontrib><creatorcontrib>Kuffel, Mary J.</creatorcontrib><creatorcontrib>Reinicke, Kathryn E.</creatorcontrib><creatorcontrib>Suman, Vera</creatorcontrib><creatorcontrib>Haluska, Paul</creatorcontrib><creatorcontrib>Hou, Xiaonan</creatorcontrib><creatorcontrib>Ames, Matthew M.</creatorcontrib><title>Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Background
Reduced CYP2D6 metabolism and low Z-endoxifen (ENDX) concentrations may increase the risk of breast cancer recurrence in tamoxifen (TAM)-treated women. Little is known regarding the differences between TAM and ENDX murine pharmacokinetics or the effect of administration route on plasma concentrations of each drug.
Methods
The pharmacokinetics of TAM and ENDX were characterized in female mice.
Results
For subcutaneous [s.c.] and oral TAM (4, 10 and 20 mg/kg), TAM AUC increased in a linear manner, but concentrations of the active metabolites [ENDX and 4-hydroxytamoxifen (4HT)] remained low. For oral TAM (20 mg), 4HT concentrations were tenfold greater (>25 ng/ml) than achievable in TAM-treated humans. Both oral (10–200 mg/kg) and s.c. (2.5–25 mg/kg) ENDX·HCl resulted in a greater than dose-proportional increase in AUC, with eightfold greater ENDX concentrations than an equivalent TAM dose. ENDX accumulated in plasma after 5-day dosing of 25 or 100 mg/kg ENDX·HCl and exceeded target concentrations of 0.1 and 1.0 μM, respectively, by twofold to fourfold.
Conclusions
In murine models, oral ENDX yields substantially higher ENDX concentrations, compared to TAM. The low 4HT and ENDX concentrations observed in mice receiving s.c. TAM mirror the TAM pharmacokinetics in humans with impaired CYP2D6 metabolism. These data support the ongoing development of ENDX as a novel agent for the endocrine treatment of ER-positive breast cancer.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Hormonal - administration & dosage</subject><subject>Antineoplastic Agents, Hormonal - pharmacokinetics</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Cytochrome P-450 CYP2D6 - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Injections, Subcutaneous</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Tamoxifen - administration & dosage</subject><subject>Tamoxifen - analogs & derivatives</subject><subject>Tamoxifen - pharmacokinetics</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU9v1DAQxS1ERZfCB-CCLCGOAf8ZxwkHJFRBi1SpPZSzNXHs1iWxt3Z2Rb89Xu1SyoHTaGZ-8-ZJj5A3nH3gjOmPhTHRsYZxaETLVKOfkRUHKRrWgXxOVkwCNEozOCYvS7ljjAGX8gU5Fkryrpftitxf3WKe0aafIbol2EKTpy6O6VfwLlKMI11wPnQhUu9mnBydg3WfaJjXU7C4hBQL9SlTm-Y15jrYuh28DdtE0dY2LA-0LJsxuPKKHHmcint9qCfkx7ev16fnzcXl2ffTLxeNVYwtzSA7L2GQSo0Ig9UwDLbl49iCRwCnbT92HnqNo7DWCm-VGkBJEAL6XmAvT8jnve56M8xutC4uGSezzmHG_GASBvPvJoZbc5O2BiRIyXcC7w4COd1vXFnMXdrkWD0b3grVcSWgqxTfUzanUrLzjx84M7uUzD4lU1Myu5SMrjdvn1p7vPgTSwXeHwAsFiefMdpQ_nIVAq1l5cSeK3UVb1x-YvG_338DDOOtWw</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Reid, Joel M.</creator><creator>Goetz, Matthew P.</creator><creator>Buhrow, Sarah A.</creator><creator>Walden, Chad</creator><creator>Safgren, Stephanie L.</creator><creator>Kuffel, Mary J.</creator><creator>Reinicke, Kathryn E.</creator><creator>Suman, Vera</creator><creator>Haluska, Paul</creator><creator>Hou, Xiaonan</creator><creator>Ames, Matthew M.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20141201</creationdate><title>Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies</title><author>Reid, Joel M. ; Goetz, Matthew P. ; Buhrow, Sarah A. ; Walden, Chad ; Safgren, Stephanie L. ; Kuffel, Mary J. ; Reinicke, Kathryn E. ; Suman, Vera ; Haluska, Paul ; Hou, Xiaonan ; Ames, Matthew M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-b38f34b355da4bc74bbc61dd64fa44e7c9d8f497ad2ccc2fc55b4534224992a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Hormonal - administration & dosage</topic><topic>Antineoplastic Agents, Hormonal - pharmacokinetics</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Cytochrome P-450 CYP2D6 - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Injections, Subcutaneous</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Tamoxifen - administration & dosage</topic><topic>Tamoxifen - analogs & derivatives</topic><topic>Tamoxifen - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reid, Joel M.</creatorcontrib><creatorcontrib>Goetz, Matthew P.</creatorcontrib><creatorcontrib>Buhrow, Sarah A.</creatorcontrib><creatorcontrib>Walden, Chad</creatorcontrib><creatorcontrib>Safgren, Stephanie L.</creatorcontrib><creatorcontrib>Kuffel, Mary J.</creatorcontrib><creatorcontrib>Reinicke, Kathryn E.</creatorcontrib><creatorcontrib>Suman, Vera</creatorcontrib><creatorcontrib>Haluska, Paul</creatorcontrib><creatorcontrib>Hou, Xiaonan</creatorcontrib><creatorcontrib>Ames, Matthew M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reid, Joel M.</au><au>Goetz, Matthew P.</au><au>Buhrow, Sarah A.</au><au>Walden, Chad</au><au>Safgren, Stephanie L.</au><au>Kuffel, Mary J.</au><au>Reinicke, Kathryn E.</au><au>Suman, Vera</au><au>Haluska, Paul</au><au>Hou, Xiaonan</au><au>Ames, Matthew M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>74</volume><issue>6</issue><spage>1271</spage><epage>1278</epage><pages>1271-1278</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Background
Reduced CYP2D6 metabolism and low Z-endoxifen (ENDX) concentrations may increase the risk of breast cancer recurrence in tamoxifen (TAM)-treated women. Little is known regarding the differences between TAM and ENDX murine pharmacokinetics or the effect of administration route on plasma concentrations of each drug.
Methods
The pharmacokinetics of TAM and ENDX were characterized in female mice.
Results
For subcutaneous [s.c.] and oral TAM (4, 10 and 20 mg/kg), TAM AUC increased in a linear manner, but concentrations of the active metabolites [ENDX and 4-hydroxytamoxifen (4HT)] remained low. For oral TAM (20 mg), 4HT concentrations were tenfold greater (>25 ng/ml) than achievable in TAM-treated humans. Both oral (10–200 mg/kg) and s.c. (2.5–25 mg/kg) ENDX·HCl resulted in a greater than dose-proportional increase in AUC, with eightfold greater ENDX concentrations than an equivalent TAM dose. ENDX accumulated in plasma after 5-day dosing of 25 or 100 mg/kg ENDX·HCl and exceeded target concentrations of 0.1 and 1.0 μM, respectively, by twofold to fourfold.
Conclusions
In murine models, oral ENDX yields substantially higher ENDX concentrations, compared to TAM. The low 4HT and ENDX concentrations observed in mice receiving s.c. TAM mirror the TAM pharmacokinetics in humans with impaired CYP2D6 metabolism. These data support the ongoing development of ENDX as a novel agent for the endocrine treatment of ER-positive breast cancer.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25318936</pmid><doi>10.1007/s00280-014-2605-7</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2014-12, Vol.74 (6), p.1271-1278 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4343319 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Administration, Oral Animals Antineoplastic agents Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - pharmacokinetics Area Under Curve Biological and medical sciences Cancer Research Cytochrome P-450 CYP2D6 - metabolism Dose-Response Relationship, Drug Female Injections, Subcutaneous Medical sciences Medicine Medicine & Public Health Mice Mice, Inbred BALB C Mice, Nude Oncology Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Tamoxifen - administration & dosage Tamoxifen - analogs & derivatives Tamoxifen - pharmacokinetics |
| title | Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T13%3A36%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20endoxifen%20and%20tamoxifen%20in%20female%20mice:%20implications%20for%20comparative%20in%20vivo%20activity%20studies&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Reid,%20Joel%20M.&rft.date=2014-12-01&rft.volume=74&rft.issue=6&rft.spage=1271&rft.epage=1278&rft.pages=1271-1278&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-014-2605-7&rft_dat=%3Cproquest_pubme%3E3499993201%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1625815248&rft_id=info:pmid/25318936&rfr_iscdi=true |